The patient must: Be age 18 or older Have eligible Medicare Part D coverage Be prescribed treatment specifically for weight reduction and maintenance Participate in ongoing nutrition and physical activity intervention Not have already received a GLP-1 through their Part D plan Not be seeking coverage for another Part D-coverable indication, such as type 2 diabetes, moderate-to-severe obstructive sleep apnea, MASH, or cardiovascular risk reduction The patient must also have met one of these criteria when GLP-1 therapy was originally started: BMI 35 BMI 30 plus HFpEF, uncontrolled hypertension despite 2 medications, or CKD stage 3a+ BMI 27 plus prediabetes, prior MI, prior stroke, or symptomatic peripheral artery disease Important: Eligibility is based on BMI at treatment initiation, not necessarily the patients current BMI
Regular use of NL-EPITHALON helps with body regeneration, improved sleep quality, immunity, and overall vitality
A personalized approach that integrates medical therapy with holistic health practices ensures optimal results
GLP-1 receptor activation supports metabolic control by: Reducing appetite and food-seeking behavior Slowing gastric emptying, which promotes earlier and longer-lasting fullness Improving the timing and efficiency of insulin release after meals This pathway helps reduce excessive calorie intake and smooth post-meal blood sugar fluctuations, which are common challenges in insulin-resistant patients
It is very important to give parents clear instructions on the timing of the necessary treatments at their first visit to reduce their anxiety during the subsequent pathway of care
